264 related articles for article (PubMed ID: 34655417)
1. Semen as a rich source of diagnostic biomarkers for prostate cancer: latest evidence and implications.
Mao C; Ding Y; Xu N
Mol Cell Biochem; 2022 Jan; 477(1):213-223. PubMed ID: 34655417
[TBL] [Abstract][Full Text] [Related]
2. Semen miRNAs Contained in Exosomes as Non-Invasive Biomarkers for Prostate Cancer Diagnosis.
Barceló M; Castells M; Bassas L; Vigués F; Larriba S
Sci Rep; 2019 Sep; 9(1):13772. PubMed ID: 31551516
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis of prostate cancer by analyzing oxidative stress in human seminal plasma: developing unsophisticated tools for noninvasive prostate cancer diagnosis.
Barrio-Muñoz M; Abad-Gairín C; Amengual-Guedán JM; Prats-López J
Eur J Cancer Prev; 2016 Nov; 25(6):518-23. PubMed ID: 26633164
[TBL] [Abstract][Full Text] [Related]
4. Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease.
Neuhaus J; Schiffer E; von Wilcke P; Bauer HW; Leung H; Siwy J; Ulrici W; Paasch U; Horn LC; Stolzenburg JU
PLoS One; 2013; 8(6):e67514. PubMed ID: 23826311
[TBL] [Abstract][Full Text] [Related]
5. Seminal fluid: a useful source of prostate cancer biomarkers?
Roberts MJ; Richards RS; Gardiner RA; Selth LA
Biomark Med; 2015; 9(2):77-80. PubMed ID: 25689895
[No Abstract] [Full Text] [Related]
6. Impact of Extracellular Vesicle Isolation Methods on Downstream Mirna Analysis in Semen: A Comparative Study.
Mercadal M; Herrero C; López-Rodrigo O; Castells M; de la Fuente A; Vigués F; Bassas L; Larriba S
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32824915
[TBL] [Abstract][Full Text] [Related]
7. Multi-omics Biomarker Pipeline Reveals Elevated Levels of Protein-glutamine Gamma-glutamyltransferase 4 in Seminal Plasma of Prostate Cancer Patients.
Drabovich AP; Saraon P; Drabovich M; Karakosta TD; Dimitromanolakis A; Hyndman ME; Jarvi K; Diamandis EP
Mol Cell Proteomics; 2019 Sep; 18(9):1807-1823. PubMed ID: 31249104
[TBL] [Abstract][Full Text] [Related]
8. Semen AMACR protein as a novel method for detecting prostate cancer.
Etheridge T; Straus J; Ritter MA; Jarrard DF; Huang W
Urol Oncol; 2018 Dec; 36(12):532.e1-532.e7. PubMed ID: 30337219
[TBL] [Abstract][Full Text] [Related]
9. Proteomics in diagnosis of prostate cancer.
Davalieva K; Polenakovic M
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):5-36. PubMed ID: 26076772
[TBL] [Abstract][Full Text] [Related]
10. The proteomics of prostate cancer exosomes.
Drake RR; Kislinger T
Expert Rev Proteomics; 2014 Apr; 11(2):167-77. PubMed ID: 24564711
[TBL] [Abstract][Full Text] [Related]
11. Elevated levels of Dickkopf-related protein 3 in seminal plasma of prostate cancer patients.
Zenzmaier C; Heitz M; Klocker H; Buck M; Gardiner RA; Berger P
J Transl Med; 2011 Nov; 9():193. PubMed ID: 22071168
[TBL] [Abstract][Full Text] [Related]
12. miRNAs as biomarkers in prostate cancer.
Casanova-Salas I; Rubio-Briones J; Fernández-Serra A; López-Guerrero JA
Clin Transl Oncol; 2012 Nov; 14(11):803-11. PubMed ID: 22855165
[TBL] [Abstract][Full Text] [Related]
13. Seminal cell-free DNA molecular profile as a novel diagnostic and prognostic prostate cancer biomarkers.
Ponti G; Maccaferri M; Manfredini M; Cotugno M; Pellacani G; Conti A; Micali S; Mandrioli M; Tomasi A
Med Hypotheses; 2018 May; 114():69. PubMed ID: 29602469
[No Abstract] [Full Text] [Related]
14. Detection and Prognosis of Prostate Cancer Using Blood-Based Biomarkers.
Jin W; Fei X; Wang X; Song Y; Chen F
Mediators Inflamm; 2020; 2020():8730608. PubMed ID: 32454797
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers for prostate cancer.
Schiffer E
World J Urol; 2007 Dec; 25(6):557-62. PubMed ID: 17690889
[TBL] [Abstract][Full Text] [Related]
16. A decrease in 1H nuclear magnetic resonance spectroscopically determined citrate in human seminal fluid accompanies the development of prostate adenocarcinoma.
Averna TA; Kline EE; Smith AY; Sillerud LO
J Urol; 2005 Feb; 173(2):433-8. PubMed ID: 15643195
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer.
Roberts MJ; Chow CW; Schirra HJ; Richards R; Buck M; Selth LA; Doi SA; Samaratunga H; Perry-Keene J; Payton D; Yaxley J; Lavin MF; Gardiner RA
Prostate; 2015 Apr; 75(5):539-49. PubMed ID: 25597828
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of the main PSA glycoforms in aggressive prostate cancer.
Gratacós-Mulleras A; Duran A; Asadi Shehni A; Ferrer-Batallé M; Ramírez M; Comet J; de Llorens R; Saldova R; Llop E; Peracaula R
Sci Rep; 2020 Nov; 10(1):18974. PubMed ID: 33149259
[TBL] [Abstract][Full Text] [Related]
19. Emerging biomarkers in the detection and prognosis of prostate cancer.
Filella X; Foj L
Clin Chem Lab Med; 2015 Jun; 53(7):963-73. PubMed ID: 25581761
[TBL] [Abstract][Full Text] [Related]
20. Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness.
Ruiz-Plazas X; Rodríguez-Gallego E; Alves M; Altuna-Coy A; Lozano-Bartolomé J; Portero-Otin M; García-Fontgivell JF; Martínez-González S; Segarra J; Chacón MR
J Transl Med; 2019 Sep; 17(1):307. PubMed ID: 31500625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
